{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:17:56Z","timestamp":1776824276336,"version":"3.51.2"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofhospitalinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hospital Infection"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jhin.2023.12.013","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T21:40:51Z","timestamp":1705441251000},"page":"118-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The cost\u2013utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country"],"prefix":"10.1016","volume":"145","author":[{"given":"T.","family":"Pungprasert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Dhirachaikulpanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Phutthasakda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tantai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Maneeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Nganthavee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Atipas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tanpong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Krithin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tanglitanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Jutidamrongphan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Chayakulkeeree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Srinonprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Phikulsod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhin.2023.12.013_bib1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/517849","article-title":"Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality\u2014SEIFEM-C Report","volume":"44","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001\u20132010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.21776","article-title":"Invasive fungal disease in patients treated for newly diagnosed acute leukemia","volume":"85","author":"Hammond","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jhin.2023.12.013_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197851","article-title":"Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study","volume":"13","author":"Lien","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhin.2023.12.013_bib5","first-page":"3613","article-title":"High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes","volume":"27","author":"Nganthavee","year":"2019"},{"key":"10.1016\/j.jhin.2023.12.013_bib6","article-title":"High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhin.2023.12.013_bib7","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/317487","article-title":"Burden of aspergillosis-related hospitalizations in the United States","volume":"31","author":"Dasbach","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1086\/502581","article-title":"Excess mortality, hospital stay, and cost due to candidemia: a case\u2013control study using data from population-based candidemia surveillance","volume":"26","author":"Morgan","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jhin.2023.12.013_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","article-title":"The direct cost and incidence of systemic fungal infections","volume":"5","author":"Wilson","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.jhin.2023.12.013_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2334-12-83","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain","volume":"12","author":"Grau","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40261-014-0199-9","article-title":"Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden","volume":"34","author":"Lundberg","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jhin.2023.12.013_bib12","first-page":"341","article-title":"An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States","volume":"18","author":"Sung","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jhin.2023.12.013_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.riam.2017.09.006","article-title":"Cost-effectiveness of posaconazole in private and public Brazilian hospitals","volume":"35","author":"Tuon","year":"2018","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.jhin.2023.12.013_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/AAC.01985-15","article-title":"Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis","volume":"60","author":"Zhao","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhin.2023.12.013_bib15","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/blood-2012-02-387092","article-title":"Meeting the challenge of hematologic malignancies in sub-Saharan Africa","volume":"119","author":"Gopal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jhin.2023.12.013_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s12098-018-2722-0","article-title":"Prevalence and predictors of invasive fungal infections in children with persistent febrile neutropenia treated for acute leukemia \u2013 a prospective study","volume":"85","author":"Kumar","year":"2018","journal-title":"Indian J Pediatr"},{"issue":"10","key":"10.1016\/j.jhin.2023.12.013_bib17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1086\/503435","article-title":"The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review","volume":"193","author":"Eckmanns","year":"2006","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib18","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib19","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2014.13985","article-title":"Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study","volume":"144","author":"Gerber","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jhin.2023.12.013_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1128\/AAC.01525-13","article-title":"Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011","volume":"58","author":"Gomes","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhin.2023.12.013_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/myc.12105","article-title":"Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis","volume":"57","author":"Heimann","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.jhin.2023.12.013_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2011.08650.x","article-title":"Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?","volume":"153","author":"Rogers","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhin.2023.12.013_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.5414\/CP201880","article-title":"Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study","volume":"51","author":"Shen","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jhin.2023.12.013_bib24","first-page":"379","article-title":"Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: a retrospective study","volume":"28","author":"Tang","year":"2018","journal-title":"J\u00a0Mycol Med"},{"key":"10.1016\/j.jhin.2023.12.013_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1318438","article-title":"SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy","volume":"58","author":"Busca","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jhin.2023.12.013_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-18","article-title":"Primary fungal prophylaxis in hematological malignancy: a network meta-analysis of randomized controlled trials","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhin.2023.12.013_bib27","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on\u00a0Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jhin.2023.12.013_bib28","first-page":"159","article-title":"Invasive fungal infection among febrile patients with chemotherapy-induced neutropenia in Thailand","volume":"48","author":"Phikulsod","year":"2017","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.jhin.2023.12.013_bib29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhin.2023.12.013_bib30","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jhin.2023.12.013_bib31","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jhin.2023.12.013_bib32","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/j.clml.2021.03.004","article-title":"Types, clinical features, and survival outcomes of patients with acute myeloid leukemia in Thailand: a 3-year prospective multicenter study from the Thai Acute Leukemia Study Group (TALSG)","volume":"21","author":"Wanitpongpun","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 5","key":"10.1016\/j.jhin.2023.12.013_bib33","first-page":"S50","article-title":"Handling time in economic evaluation studies","volume":"97","author":"Permsuwan","year":"2014","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.jhin.2023.12.013_bib34","series-title":"Guidelines for health technology assessment in Thailand","author":"Chaikledkaew","year":"2013"},{"key":"10.1016\/j.jhin.2023.12.013_bib36","author":"Riewpaiboon"},{"key":"10.1016\/j.jhin.2023.12.013_bib37","series-title":"Consumer price index. Business of trade and economics indices","author":"Udomchai","year":"2021"},{"key":"10.1016\/j.jhin.2023.12.013_bib39","series-title":"Assessing a societal value for a ceiling threshold in Thailand. Health intervention and technology assessment program (HITAP)","author":"Thavorncharoensap","year":"2013"},{"key":"10.1016\/j.jhin.2023.12.013_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jhin.2023.12.013_bib41","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhin.2023.12.013_bib42","doi-asserted-by":"crossref","first-page":"A806","DOI":"10.1016\/j.jval.2014.08.522","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prophylaxis of invasive fungal infections among neutropenic patients in Thailand","volume":"17","author":"Junjarunee","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jhin.2023.12.013_bib43","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jval.2011.05.032","article-title":"Costo Efectividad de Posaconazol versus Fluconazol\/Itraconazol en el Tratamiento Profil\u00e1ctico de las Infecciones F\u00fangicas Invasivas en M\u00e9xico","volume":"14","author":"Rely","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jhin.2023.12.013_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00019053-200826010-00007","article-title":"Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections","volume":"26","author":"de Vries","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhin.2023.12.013_bib45","first-page":"28","article-title":"Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system","volume":"14","author":"Michallet","year":"2011","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jhin.2023.12.013_bib46","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1524-4733.2008.00486.x","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States","volume":"12","author":"O'Sullivan","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jhin.2023.12.013_bib47","first-page":"77","article-title":"Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital","volume":"19","author":"Chan","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jhin.2023.12.013_bib48","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/jac\/dkq076","article-title":"Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia","volume":"65","author":"Al-Badriyeh","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jhin.2023.12.013_bib49","article-title":"Industry sponsorship bias in cost effectiveness analysis: registry based analysis","volume":"377","author":"Xie","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jhin.2023.12.013_bib50","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jhin.2023.12.013_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2023.12.013_bib52","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhin.2023.12.013_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S6321","article-title":"Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections","volume":"2","author":"Neofytos","year":"2010","journal-title":"Drug Healthc Patient Saf"}],"container-title":["Journal of Hospital Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670124000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670124000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:24:22Z","timestamp":1759292662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195670124000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":51,"alternative-id":["S0195670124000045"],"URL":"https:\/\/doi.org\/10.1016\/j.jhin.2023.12.013","relation":{},"ISSN":["0195-6701"],"issn-type":[{"value":"0195-6701","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost\u2013utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country","name":"articletitle","label":"Article Title"},{"value":"Journal of Hospital Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhin.2023.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society.","name":"copyright","label":"Copyright"}]}}